• Preventive Nutrition and Food Science
• /
• 제11권2호
• /
• pp.120-126
• /
• 2006

Fish backbone, a major by-product in the fish processing industry, accounts for about 15% of whole fish weight. In this study, recovery of bioavailable calcium from Alaska pollack (Theragra chalcogramma) backbone by-products using enzymatic hydrolysis was investigated. Finely ground fish backbones were hydrolyzed with two proteolytic enzymes (pepsin and protease) to obtain soluble calcium from the by-products. The pepsin digest had a higher degradation efficiency (88%) than protease. Four different concentrations of the fish backbone calcium (100, 250, 500 and 1000 mg/L) prepared by the pepsin digest were treated with $Na_2HPO_4$ at a concentration gradient (0, 1, 2, 4, 8, 10, 15 and 20 mM) to evaluate their solubility, revealing that solubilities of the fish backbone calcium were superior to those of $CaCl_2$ at all the calcium and $Na_2HPO_4$ concentrations. Among the tested concentrations the highest solubility was found in the pepsin digest containing a calcium concentration of 1000 mg/L. Thus, hydrolyzing with pepsin is an effective mode of recovering bioavailable calcium from Alaska pollack fish backbones.

• 한국식품과학회지
• /
• 제28권6호
• /
• pp.995-1000
• /
• 1996

본 실험은 두유에 칼슘을 강화하기 위해 두유 단백질의 칼슘내인성을 높이기 위한 방법으로 두유 단백질을 부분가수분해시킬 최적 단백분해효소 및 그의 최적 처리조건을 결정하였고, 효소처리한 뒤 칼슘염을 첨가하여 제조된 칼슘강화 두유의 체외소화시 단백질과 칼슘의 소화특성을 조사하였다. 두유에 처리된 4가지 단백분해효소 중에서 Bacillus polymyxa의 단백분해효소가 pH 7.5, $50^{\circ}C$, 10min의 처리조건하에서 처리 후 두유에 쓴맛을 남기지 않고, 칼슘염을 첨가하였을 때 응고현상을 가장 적게 나타내는 것으로 밝혀졌다. 또 가수분해 정도가 증가할수록 칼슘에 의한 응고정도는 감소했으나 10분 이후부터는 쓴맛이 감지되었으므로 효소처리시간은 10분으로 결정하였다. 두유에 효소처리를 한 뒤 염화칼슘을 5, 15, 25 mM 첨가하여 칼슘강화 두유를 제조하여 단백질의 체외소화율을 분석한 결과, 두유에 첨가된 칼슘의 농도와 무관하게 모든 칼슘강화 두유가 표준두유와 유사한 소화율을 나타냈다. 소화전에는 표준두유에 비해 효소처리만 한 두유의 가용성 칼슘이 약간 높으면서 이온형태의 것은 적게 나타났으며 효소처리 후 염화칼슘을 5, 15, 25 mM 첨가하여 만든 칼슘강화 두유는 이온형태의 칼슘함량이 점차 증가하였다. 펩신을 처리하였을 때는 가용성칼슘이 거의 이온형태의 것으로 나타났으며 두유에 칼슘이 많이 강화될수록 유리되는 이온형태의 칼슘함량도 증가하였다. 이상의 결과를 미루어 볼 때, 우유와 비슷한 수준으로 칼슘이 첨가된 두유도 단백질의 체외 소화율은 감소되지 않았으며, 소화시 체내에 흡수될 수 있는 이온 형태의 칼슘의 양은 첨가량과 비례하였으므로 이와 같은 방법으로 칼슘강화 두유를 제조할 때 칼슘의 체내 이용도는 증가할 수 있을 것으로 생각된다.

• Environmental Engineering Research
• /
• 제24권4호
• /
• pp.654-661
• /
• 2019

This study assessed the stabilization of fluorine (F)-contaminated soil using calcium hydroxide (Ca(OH)₂) and the consequent changes in human health risk. The bioavailable F decreased to 3.5%, (i.e., 57.9 ± 1.27 mg/kg in 6% Ca(OH)₂-treated soil sample) from 43.0%, (i.e., 711 ± 23.4 mg/kg in control soil sample). This resulted from the conversion of water-soluble F to stable calcium fluoride, which was confirmed by XRD spectrometry. Soil ingestion, inhalation of fugitive dust from soil, and water ingestion were selected as exposure pathways for human health risk assessment. Non-carcinogenic risks of F in soils reduced to less than 1.0 after stabilization, ranging from 4.2 to 0.34 for child and from 3.0 to 0.25 for adult. Contaminated water ingestion owing to the leaching of F from soil to groundwater was considered as a major exposure pathway. The risks through soil ingestion and inhalation of fugitive dust from soil were insignificant both before and after stabilization, although F concentration exceeded the Korean soil regulatory level before stabilization. Our data suggested that substantial risk to human health owing to various potential exposure pathways could be addressed by managing F present in soil.

• Biomolecules & Therapeutics
• /
• 제27권3호
• /
• pp.327-335
• /
• 2019

As the elderly population is increasing, Alzheimer's disease (AD) has become a global issue and many clinical trials have been conducted to evaluate treatments for AD. As these clinical trials have been conducted and have failed, the development of new theraphies for AD with fewer adverse effects remains a challenge. In this study, we examined the effects of Theracurmin on cognitive decline using 5XFAD mice, an AD mouse model. Theracurmin is more bioavailable form of curcumin, generated with submicron colloidal dispersion. Mice were treated with Theracurmin (100, 300 and 1,000 mg/kg) for 12 weeks and were subjected to the novel object recognition test and the Barnes maze test. Theracurmin-treated mice showed significant amelioration in recognition and spatial memories compared those of the vehicle-treated controls. In addition, the antioxidant activities of Theracurmin were investigated by measuring the superoxide dismutase (SOD) activity, malondialdehyde (MDA) and glutathione (GSH) levels. The increased MDA level and decreased SOD and GSH levels in the vehicle-treated 5XFAD mice were significantly reversed by the administration of Theracurmin. Moreover, we observed that Theracurmin administration elevated the expression levels of synaptic components, including synaptophysin and post synaptic density protein 95, and decreased the expression levels of ionized calcium-binding adapter molecule 1 (Iba-1), a marker of activated microglia. These results suggest that Theracurmin ameliorates cognitive function by increasing the expression of synaptic components and by preventing neuronal cell damage from oxidative stress or from the activation of microglia. Thus, Theracurmin would be useful for treating the cognitive dysfunctions observed in AD.